Showing 2491-2500 of 5977 results for "".
- Indoor Tanning Linked to Anxiety, Depressionhttps://practicaldermatology.com/news/indoor-tanning-linked-to-anxiety-depression/2460808/Indoor tanning early in life is associated with risk of anxiety and depression later in life, according to new research in the Journal of the American Academy of Dermatology. Excluding women wi
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas
- It's a RAP: Allergan Set to Acquire Solitonhttps://practicaldermatology.com/news/deal-time-allergan-set-to-acquire-soliton/2460801/Allergan Aesthetics is set to acquire Soliton and Resonic, its Rapid Acoustic Pulse device. Resonic recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The ac
- CorEvitas Enrolls 15,000 Patients in its Psoriasis and AD Registrieshttps://practicaldermatology.com/news/corevitas-enrolls-15000-patients-in-its-psoriasis-and-ad-registries/2460795/CorEvitas has enrolled more than 15,000 patients with immune-mediated skin diseases in the CorEvitas registries for moderate to severe psoriasis and atopic dermatitis (AD). This milestone was achieved by building on the company's real-world evidence program and dermatolog
- Henry Ford Innovations, Google Cloud, and Miracle Software Systems to Fund Innovations Focused on Health Inequitieshttps://practicaldermatology.com/news/henry-ford-innovations-google-cloud-and-miracle-software-systems-to-fund-innovations-focused-on-health-inequities/2460782/Entrepreneurs with ideas for reducing health inequities through the use of digital technology could garner $75,000 in cash and in-kind support toward developing their digital solution at Henry Ford Health System.
- Cynosure Expands Its Potenza RF Microneedling System with New Fusion Tip for Enhanced Topical Penetrationhttps://practicaldermatology.com/news/cynosure-expands-its-potenza-rf-microneedling-system-with-new-fusion-tip-for-enhanced-topical-penetration/2460781/The Fusion Tip is the latest addition to Cynosure's Potenza system, its four-mode RF microneedling device, which uses ultrafine needles and RF energy to penetrate the top layer of the skin, triggering the body's natural healing process to regenerate new collagen and elastin.
- Daily Avena Sativa Skincare Regimen Improves Itch and Dry Skin in Adults Undergoing Systemic Cancer Treatmentshttps://practicaldermatology.com/news/daily-avena-sativa-skincare-regimen-improves-itch-and-dry-skin-in-adults-undergoing-systemic-cancer-treatments-1/2460780/Daily Avena Sativa (Oat) skincare regimen provides a significant improvement in xerosis and pruritus for adult patients undergoing systemic oncology treatments,according to research presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021. "The u
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD
- Biosimilar News: Switching Study Shows Cyltezo and Humira Are Interchangeablehttps://practicaldermatology.com/news/biosimilar-news-switching-study-shows-cyltezo-and-humira-are-interchangeable/2460762/Switching between adalimumab biosimilar Cyltezo and its reference product results in similar pharmacokinetics, efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis, according to new Phase 3 data presented at the American Academy of Dermatology 2021 virtua